A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population

Journal of Managed Care & Specialty Pharmacy
Alpesh AminL Vo

Abstract

Clinical trials have shown that direct oral anticoagulants (DOACs)-including dabigatran, rivaroxaban, apixaban, and edoxaban-are at least as effective and safe as warfarin for the risk of stroke/systemic embolism (SE) and major bleeding (MB) in patients with atrial fibrillation (AF). However, few studies have compared oral anticoagulants (OACs) among elderly patients. To compare hospitalization risks (all-cause, stroke/SE-related, and MB-related) and associated health care costs among elderly nonvalvular AF (NVAF) patients in the Medicare population who initiated warfarin, dabigatran, rivaroxaban, or apixaban. Patients (aged ≥ 65 years) initiating warfarin or DOACs (apixaban, rivaroxaban, and dabigatran) were selected from the Centers for Medicare & Medicaid Services database from January 1, 2013, to December 31, 2014. Patients initiating each OAC were matched 1:1 to apixaban patients using propensity score matching to balance demographic and clinical characteristics. Cox proportional hazards models were used to estimate the risk of hospitalization of each OAC versus apixaban. Generalized linear models and two-part models with bootstrapping were used to compare all-cause health care costs and stroke/SE- and MB-related medical c...Continue Reading

References

May 21, 2008·Circulation·Julie B Shea, Samuel F Sears
Jan 1, 2008·Journal of Medical Economics·Won Chan LeeChris L Pashos
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Mar 10, 2011·Pharmacoepidemiology and Drug Safety·Andrew CunninghamWayne A Ray
May 5, 2011·Circulation. Cardiovascular Quality and Outcomes·Michael H KimKathy L Schulman
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Jan 25, 2012·Pharmacoepidemiology and Drug Safety·Paul N JensenSascha Dublin
Apr 4, 2013·Stroke; a Journal of Cerebral Circulation·Amanda R HarringtonDaniel C Malone
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Aug 13, 2014·Nature Reviews. Cardiology·Faisal RahmanEmelia J Benjamin
Jan 7, 2016·Circulation. Cardiovascular Quality and Outcomes·Ritu Sachdeva, Pamela S Douglas
Jul 15, 2016·Journal of the American Heart Association·Xiaoxi YaoPeter A Noseworthy
Jan 25, 2018·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Steve DeitelzweigJay Lin

❮ Previous
Next ❯

Citations

Jan 21, 2020·Expert Review of Hematology·Jennifer L KoehlRachel Rosovsky
Jun 9, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Antonios DourosKristian B Filion
Sep 9, 2020·Journal of Medical Economics·Dejan MilentijevicPatrick Lefebvre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

© 2022 Meta ULC. All rights reserved